The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression
of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The …

Antiphospholipid syndrome (APS) is an autoimmune thrombophilia propelled by circulating
antiphospholipid antibodies that herald vascular thrombosis and obstetrical complications …

Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …

Abstract Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), continues to spread globally despite the worldwide …

Immune-related manifestations are increasingly recognized conditions in patients with
COVID-19, with around 3,000 cases reported worldwide comprising more than 70 different …

More than one and a half years have elapsed since the commencement of the coronavirus
disease 2019 (COVID-19) pandemic, and the world is struggling to contain it. Being caused …

Background Many studies reported high prevalence of antiphospholipid antibodies (aPL) in
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

Background: Numerous cases of the coronavirus disease 2019 (COVID-19) with
autoimmune and rheumatic manifestations have been reported. Despite the available …